Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02966873 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial for Alcohol Use Disorder and Post Traumatic Stress Disorder (PTSD)
A Phase 2 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 2
- Development phase
- 182
- Enrollment target
NCT02966873: Completed Phase 2 study, sponsored by Medical University of South Carolina.
NCT02966873 is a Phase 2 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 182 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (37% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02966873, a Phase 2 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 182 participants
- Enrollment target
Study Summary
This is a randomized controlled Phase II clinical trial designed to evaluate the effects of N-acetylcysteine (NAC) in reducing Alcohol Use Disorder (AUD) severity and Post Traumatic Stress Disorder (PTSD) symptomatology among individuals with current AUD and PTSD.
Primary Outcome
Change in Alcohol Use Severity as measured by standard drinks per day using the Time Line Follow Back (TLFB) to measure alcohol consumption. Fewer standard drinks per day represent better outcomes. Greater change in standard drinks per day represents better outcomes.
Interventions
- BEHAVIORAL Cognitive Behavioral Therapy (CBT)
- OTHER Functional magnetic resonance imaging (fMRI)
- DRUG N-Acetylcysteine (NAC) Treatment
- DRUG Inactive Placebo Oral Capsule
- OTHER Proton magnetic resonance spectroscopy (MRS) Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2016-10-01 |
| Est. Completion | 2022-09-19 |
| Phase | Phase 2 |
What the finished NCT02966873 record still lists
NCT02966873 is an interventional study that assigns participants to a tested intervention. The registered 182 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (37% higher).
The record links to 0 conditions, and to 5 interventions - of which Cognitive Behavioral Therapy (CBT) is the first listed.
NCT02966873 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02966873 about?
NCT02966873 is a clinical study titled "Clinical Trial for Alcohol Use Disorder and Post Traumatic Stress Disorder (PTSD)". This is a randomized controlled Phase II clinical trial designed to evaluate the effects of N-acetylcysteine (NAC) in reducing Alcohol Use Disorder (AUD) severity and Post Traumatic Stress Disorder (PTSD) symptomatology among individuals with current AUD and PTSD.
What is the current status of trial NCT02966873?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 182 participants. The study started on 2016-10-01. Estimated completion is 2022-09-19.
What interventions are being tested in trial NCT02966873?
The interventions under investigation include: Cognitive Behavioral Therapy (CBT) (BEHAVIORAL), Functional magnetic resonance imaging (fMRI) (OTHER), N-Acetylcysteine (NAC) Treatment (DRUG), Inactive Placebo Oral Capsule (DRUG), Proton magnetic resonance spectroscopy (MRS) Imaging (OTHER).
Who is sponsoring clinical trial NCT02966873?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02966873's enrollment target sits among peer trials
182 363rd of 2000 higher than 1,636 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- NCT04323735 · 182 participants · Phase 2
Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters
- NCT05606731 · 182 participants · NA
Family Intervention to Prevent Childhood Obesity
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI